English
简体中文
Total: £ 56.28
Published Date: 2025-10-17 | Pages: 128 | Tables: 124 | Medical Care
The global Autologous CAR-T Cell Therapy market is projected to grow from US$ 4437 million in 2024 to US$ 17630 million by 2031, at a CAGR of 22.1% (2025-2031), driven by critical product segments and diverse end‑use applications.
CAR-T cell therapy is a novel immunotherapy method, abbreviated as chimeric antigen receptor T cells. Autologous CAR-T cell therapy uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.
Cell immunotherapy techniques, represented by chimeric antigen receptor T-cell immunotherapy (CAR-T therapy), express CAR fusion proteins on the surface of T cells through genetic engineering technology. The CAR extracellular antigen recognition region (one of the components of CAR cells, responsible for recognizing tumor cell surface antigens) can specifically recognize tumor antigens and transmit signals into cells to activate T cells, achieving proliferation and targeted killing of tumor cells. CAR-T therapy has shown breakthrough efficacy and enormous potential for development and market prospects for cancer patients who are unable to cope with traditional treatments. CAR-T cells are divided into autologous and allogeneic CAR-T cells. At present, CAR-T therapy mainly uses autologous CAR-T cells.
In recent years, the progress of autologous CAR-T cell therapy in hematological tumors has inspired scientists to extend this technology to the treatment of solid tumors. However, the current progress in the treatment of solid tumors is relatively slow. But in the future, with the discovery of more targets and the development of clinical trials, solid tumors are expected to become the main treatment area for CAR-T. At present, JW (Cayman) Therapeutics is laying out more innovative products to officially enter the field of cell therapy for solid tumors.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Autologous CAR-T Cell Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novartis
Gilead (Kite Pharma)
Bristol Myers Squibb
Fosun Kite Biotechnology
JW Therapeutics
Bluebird Bio
IASO Bio
Juventas Cell Therapy
Legend Biotech
CARsge
Segment by Type
Target: CD19
Target: BCMA
Segment by Application
Hematological Tumors
Solid Tumor
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Autologous CAR-T Cell Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Autologous CAR-T Cell Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Autologous CAR-T Cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Target: CD19
1.2.3 Target: BCMA
1.3 Market Segmentation by Application
1.3.1 Global Autologous CAR-T Cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hematological Tumors
1.3.3 Solid Tumor
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Autologous CAR-T Cell Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Autologous CAR-T Cell Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Autologous CAR-T Cell Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Autologous CAR-T Cell Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Target: CD19 Market Size by Players
3.3.2 Target: BCMA Market Size by Players
3.4 Global Autologous CAR-T Cell Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Autologous CAR-T Cell Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Autologous CAR-T Cell Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Autologous CAR-T Cell Therapy Market Size by Type (2020-2031)
6.4 North America Autologous CAR-T Cell Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Autologous CAR-T Cell Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Autologous CAR-T Cell Therapy Market Size by Type (2020-2031)
7.4 Europe Autologous CAR-T Cell Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Autologous CAR-T Cell Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Autologous CAR-T Cell Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Autologous CAR-T Cell Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Autologous CAR-T Cell Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Autologous CAR-T Cell Therapy Market Size by Type (2020-2031)
9.4 Central and South America Autologous CAR-T Cell Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Autologous CAR-T Cell Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Autologous CAR-T Cell Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Autologous CAR-T Cell Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Autologous CAR-T Cell Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis Autologous CAR-T Cell Therapy Product Features and Attributes
11.1.4 Novartis Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Novartis Autologous CAR-T Cell Therapy Revenue by Product in 2024
11.1.6 Novartis Autologous CAR-T Cell Therapy Revenue by Application in 2024
11.1.7 Novartis Autologous CAR-T Cell Therapy Revenue by Geographic Area in 2024
11.1.8 Novartis Autologous CAR-T Cell Therapy SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 Gilead (Kite Pharma)
11.2.1 Gilead (Kite Pharma) Corporation Information
11.2.2 Gilead (Kite Pharma) Business Overview
11.2.3 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Product Features and Attributes
11.2.4 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Revenue by Product in 2024
11.2.6 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Revenue by Application in 2024
11.2.7 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Revenue by Geographic Area in 2024
11.2.8 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy SWOT Analysis
11.2.9 Gilead (Kite Pharma) Recent Developments
11.3 Bristol Myers Squibb
11.3.1 Bristol Myers Squibb Corporation Information
11.3.2 Bristol Myers Squibb Business Overview
11.3.3 Bristol Myers Squibb Autologous CAR-T Cell Therapy Product Features and Attributes
11.3.4 Bristol Myers Squibb Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Bristol Myers Squibb Autologous CAR-T Cell Therapy Revenue by Product in 2024
11.3.6 Bristol Myers Squibb Autologous CAR-T Cell Therapy Revenue by Application in 2024
11.3.7 Bristol Myers Squibb Autologous CAR-T Cell Therapy Revenue by Geographic Area in 2024
11.3.8 Bristol Myers Squibb Autologous CAR-T Cell Therapy SWOT Analysis
11.3.9 Bristol Myers Squibb Recent Developments
11.4 Fosun Kite Biotechnology
11.4.1 Fosun Kite Biotechnology Corporation Information
11.4.2 Fosun Kite Biotechnology Business Overview
11.4.3 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Product Features and Attributes
11.4.4 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Revenue by Product in 2024
11.4.6 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Revenue by Application in 2024
11.4.7 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Revenue by Geographic Area in 2024
11.4.8 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy SWOT Analysis
11.4.9 Fosun Kite Biotechnology Recent Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Corporation Information
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics Autologous CAR-T Cell Therapy Product Features and Attributes
11.5.4 JW Therapeutics Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.5.5 JW Therapeutics Autologous CAR-T Cell Therapy Revenue by Product in 2024
11.5.6 JW Therapeutics Autologous CAR-T Cell Therapy Revenue by Application in 2024
11.5.7 JW Therapeutics Autologous CAR-T Cell Therapy Revenue by Geographic Area in 2024
11.5.8 JW Therapeutics Autologous CAR-T Cell Therapy SWOT Analysis
11.5.9 JW Therapeutics Recent Developments
11.6 Bluebird Bio
11.6.1 Bluebird Bio Corporation Information
11.6.2 Bluebird Bio Business Overview
11.6.3 Bluebird Bio Autologous CAR-T Cell Therapy Product Features and Attributes
11.6.4 Bluebird Bio Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Bluebird Bio Recent Developments
11.7 IASO Bio
11.7.1 IASO Bio Corporation Information
11.7.2 IASO Bio Business Overview
11.7.3 IASO Bio Autologous CAR-T Cell Therapy Product Features and Attributes
11.7.4 IASO Bio Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.7.5 IASO Bio Recent Developments
11.8 Juventas Cell Therapy
11.8.1 Juventas Cell Therapy Corporation Information
11.8.2 Juventas Cell Therapy Business Overview
11.8.3 Juventas Cell Therapy Autologous CAR-T Cell Therapy Product Features and Attributes
11.8.4 Juventas Cell Therapy Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Juventas Cell Therapy Recent Developments
11.9 Legend Biotech
11.9.1 Legend Biotech Corporation Information
11.9.2 Legend Biotech Business Overview
11.9.3 Legend Biotech Autologous CAR-T Cell Therapy Product Features and Attributes
11.9.4 Legend Biotech Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Legend Biotech Recent Developments
11.10 CARsge
11.10.1 CARsge Corporation Information
11.10.2 CARsge Business Overview
11.10.3 CARsge Autologous CAR-T Cell Therapy Product Features and Attributes
11.10.4 CARsge Autologous CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Autologous CAR-T Cell TherapyIndustry Chain Analysis
12.1 Autologous CAR-T Cell Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Autologous CAR-T Cell Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Autologous CAR-T Cell Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Autologous CAR-T Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Autologous CAR-T Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Autologous CAR-T Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Autologous CAR-T Cell Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Autologous CAR-T Cell Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Autologous CAR-T Cell Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Autologous CAR-T Cell Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Autologous CAR-T Cell Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autologous CAR-T Cell Therapy as of 2024)
Table 11. Global Autologous CAR-T Cell Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Autologous CAR-T Cell Therapy Companies Headquarters
Table 13. Global Autologous CAR-T Cell Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Autologous CAR-T Cell Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Autologous CAR-T Cell Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Autologous CAR-T Cell Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Autologous CAR-T Cell Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Autologous CAR-T Cell Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Autologous CAR-T Cell Therapy Growth Accelerators and Market Barriers
Table 25. North America Autologous CAR-T Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Autologous CAR-T Cell Therapy Growth Accelerators and Market Barriers
Table 27. Europe Autologous CAR-T Cell Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Autologous CAR-T Cell Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Autologous CAR-T Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Autologous CAR-T Cell Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America Autologous CAR-T Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Autologous CAR-T Cell Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Autologous CAR-T Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Novartis Corporation Information
Table 35. Novartis Description and Major Businesses
Table 36. Novartis Product Features and Attributes
Table 37. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Novartis Revenue Proportion by Product in 2024
Table 39. Novartis Revenue Proportion by Application in 2024
Table 40. Novartis Revenue Proportion by Geographic Area in 2024
Table 41. Novartis Autologous CAR-T Cell Therapy SWOT Analysis
Table 42. Novartis Recent Developments
Table 43. Gilead (Kite Pharma) Corporation Information
Table 44. Gilead (Kite Pharma) Description and Major Businesses
Table 45. Gilead (Kite Pharma) Product Features and Attributes
Table 46. Gilead (Kite Pharma) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Gilead (Kite Pharma) Revenue Proportion by Product in 2024
Table 48. Gilead (Kite Pharma) Revenue Proportion by Application in 2024
Table 49. Gilead (Kite Pharma) Revenue Proportion by Geographic Area in 2024
Table 50. Gilead (Kite Pharma) Autologous CAR-T Cell Therapy SWOT Analysis
Table 51. Gilead (Kite Pharma) Recent Developments
Table 52. Bristol Myers Squibb Corporation Information
Table 53. Bristol Myers Squibb Description and Major Businesses
Table 54. Bristol Myers Squibb Product Features and Attributes
Table 55. Bristol Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Bristol Myers Squibb Revenue Proportion by Product in 2024
Table 57. Bristol Myers Squibb Revenue Proportion by Application in 2024
Table 58. Bristol Myers Squibb Revenue Proportion by Geographic Area in 2024
Table 59. Bristol Myers Squibb Autologous CAR-T Cell Therapy SWOT Analysis
Table 60. Bristol Myers Squibb Recent Developments
Table 61. Fosun Kite Biotechnology Corporation Information
Table 62. Fosun Kite Biotechnology Description and Major Businesses
Table 63. Fosun Kite Biotechnology Product Features and Attributes
Table 64. Fosun Kite Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Fosun Kite Biotechnology Revenue Proportion by Product in 2024
Table 66. Fosun Kite Biotechnology Revenue Proportion by Application in 2024
Table 67. Fosun Kite Biotechnology Revenue Proportion by Geographic Area in 2024
Table 68. Fosun Kite Biotechnology Autologous CAR-T Cell Therapy SWOT Analysis
Table 69. Fosun Kite Biotechnology Recent Developments
Table 70. JW Therapeutics Corporation Information
Table 71. JW Therapeutics Description and Major Businesses
Table 72. JW Therapeutics Product Features and Attributes
Table 73. JW Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. JW Therapeutics Revenue Proportion by Product in 2024
Table 75. JW Therapeutics Revenue Proportion by Application in 2024
Table 76. JW Therapeutics Revenue Proportion by Geographic Area in 2024
Table 77. JW Therapeutics Autologous CAR-T Cell Therapy SWOT Analysis
Table 78. JW Therapeutics Recent Developments
Table 79. Bluebird Bio Corporation Information
Table 80. Bluebird Bio Description and Major Businesses
Table 81. Bluebird Bio Product Features and Attributes
Table 82. Bluebird Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Bluebird Bio Recent Developments
Table 84. IASO Bio Corporation Information
Table 85. IASO Bio Description and Major Businesses
Table 86. IASO Bio Product Features and Attributes
Table 87. IASO Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. IASO Bio Recent Developments
Table 89. Juventas Cell Therapy Corporation Information
Table 90. Juventas Cell Therapy Description and Major Businesses
Table 91. Juventas Cell Therapy Product Features and Attributes
Table 92. Juventas Cell Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Juventas Cell Therapy Recent Developments
Table 94. Legend Biotech Corporation Information
Table 95. Legend Biotech Description and Major Businesses
Table 96. Legend Biotech Product Features and Attributes
Table 97. Legend Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Legend Biotech Recent Developments
Table 99. CARsge Corporation Information
Table 100. CARsge Description and Major Businesses
Table 101. CARsge Product Features and Attributes
Table 102. CARsge Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. CARsge Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Autologous CAR-T Cell Therapy Product Picture
Figure 2. Global Autologous CAR-T Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Target: CD19 Product Picture
Figure 4. Target: BCMA Product Picture
Figure 5. Global Autologous CAR-T Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hematological Tumors
Figure 7. Solid Tumor
Figure 8. Autologous CAR-T Cell Therapy Report Years Considered
Figure 9. Global Autologous CAR-T Cell Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 11. Global Autologous CAR-T Cell Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Autologous CAR-T Cell Therapy Revenue Market Share by Region (2020-2031)
Figure 13. Global Autologous CAR-T Cell Therapy Revenue Market Share Ranking (2024)
Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 15. Target: CD19 Revenue Market Share by Player in 2024
Figure 16. Target: BCMA Revenue Market Share by Player in 2024
Figure 17. Global Autologous CAR-T Cell Therapy Revenue Market Share by Type (2020-2031)
Figure 18. Global Autologous CAR-T Cell Therapy Revenue Market Share by Application (2020-2031)
Figure 19. North America Autologous CAR-T Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 20. North America Top 5 Players Autologous CAR-T Cell Therapy Revenue (US$ Million) in 2024
Figure 21. North America Autologous CAR-T Cell Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 22. North America Autologous CAR-T Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 23. US Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 24. Canada Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 25. Mexico Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 26. Europe Autologous CAR-T Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 27. Europe Top 5 Players Autologous CAR-T Cell Therapy Revenue (US$ Million) in 2024
Figure 28. Europe Autologous CAR-T Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 29. Europe Autologous CAR-T Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 30. Germany Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 31. France Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 32. U.K. Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. Italy Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Russia Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Autologous CAR-T Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Top 8 Players Autologous CAR-T Cell Therapy Revenue (US$ Million) in 2024
Figure 37. Asia-Pacific Autologous CAR-T Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 38. Asia-Pacific Autologous CAR-T Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 39. Indonesia Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 40. Japan Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. South Korea Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. Australia Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. India Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. Indonesia Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 45. Vietnam Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 46. Malaysia Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 47. Philippines Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Singapore Autologous CAR-T Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Central and South America Autologous CAR-T Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Central and South America Top 5 Players Autologous CAR-T Cell Therapy Revenue (US$ Million) in 2024
Figure 51. Central and South America Autologous CAR-T Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 52. Central and South America Autologous CAR-T Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 53. Brazil Autologous CAR-T Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 54. Argentina Autologous CAR-T Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 55. Middle East and Africa Autologous CAR-T Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Middle East and Africa Top 5 Players Autologous CAR-T Cell Therapy Revenue (US$ Million) in 2024
Figure 57. South America Autologous CAR-T Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 58. Middle East and Africa Autologous CAR-T Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 59. GCC Countries Autologous CAR-T Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 60. Israel Autologous CAR-T Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 61. Egypt Autologous CAR-T Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 62. South Africa Autologous CAR-T Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Autologous CAR-T Cell Therapy Industry Chain Mapping
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
